Severe Mpox Case Confirmed in New York City

A resident of New York City has tested positive for severe mpox (previously known as monkeypox), as reported by the city’s Department of Health.

This particular case involves mpox clade I, which is one of the two primary groups of mpox viruses associated with the disease. Dr. Mark Siegel, a senior medical analyst, stated that “Clade I can lead to more severe symptoms and has the potential to be life-threatening.” He noted that it can spread through events like direct contact, sexual activity, and respiratory droplets, although it isn’t transmitted over long distances via respiratory means.

Interestingly, Clade II was the strain responsible for the pandemic in 2022, boasting a survival rate of over 99.9%. In contrast, Clade I has been linked to a recent outbreak in the Democratic Republic of the Congo and is known to cause more severe illness and fatalities.

The patient from New York recently traveled outside the state, suggesting that this case is likely travel-related and not indicative of local transmission, according to Siegel.

Dr. Alistair Martin, the Health Commissioner for New York City, mentioned that there is currently no known community transmission of mpox clade I in the city, and the overall risk for residents remains low.

To minimize the risk of infection, the Department of Health encourages individuals considered at risk for mpox to receive the two-dose vaccine series, which has been shown to be effective. This recommendation extends to men aged 18 and older who identify as gay, bisexual, or have sexual contact with men, as well as those with specific other risk factors. Additionally, travelers heading to areas where Clade I mpox is common should also consider vaccination.

For anyone who may have come into close contact with an infected individual, vaccination should ideally occur within a 14-day window. Vulnerable populations, especially those with weakened immune systems and young children, are at greater risk for serious complications from the virus.

Experts highlight that receiving the vaccine can also reduce the severity of symptoms if infection occurs. The two-dose JYNNEOS vaccine is recognized as the most common form of preventive care. It’s worth noting that people who have already contracted mpox do not require vaccination.

Common symptoms associated with mpox include painful blistering rashes that can appear on various parts of the body, as well as fever, chills, fatigue, muscle aches, headaches, swollen lymph nodes, and respiratory issues. Typically, these symptoms surface one to three weeks following exposure.

In rare occurrences, mpox can lead to more serious complications such as eye infections, severe rashes, painful skin lesions, and neurological issues.

Treatment mostly involves supportive care to alleviate symptoms, but in severe instances, an antiviral drug called TPOXX (tecovirimat) may be utilized, as noted by Siegel.